Academic Integrity: tutoring, explanations, and feedback — we don’t complete graded work or submit on a student’s behalf.

The comparative balance sheet of Livers Inc. for December 31, 20Y3 and 20Y2, is

ID: 2600025 • Letter: T

Question

The comparative balance sheet of Livers Inc. for December 31, 20Y3 and 20Y2, is as follows:

1

Dec. 31, 20Y3

Dec. 31, 20Y2

2

Assets

3

Cash

$625,820.00

$586,050.00

4

Accounts receivable (net)

227,530.00

209,880.00

5

Inventories

641,480.00

616,920.00

6

Investments

0.00

240,910.00

7

Land

327,510.00

0.00

8

Equipment

704,830.00

554,110.00

9

Accumulated depreciation-equipment

(165,750.00)

(148,570.00)

10

Total assets

$2,361,420.00

$2,059,300.00

11

Liabilities and Stockholders’ Equity

12

Accounts payable (merchandise creditors)

$424,970.00

$405,330.00

13

Accrued expenses payable (operating expenses)

42,810.00

51,640.00

14

Dividends payable

23,200.00

19,840.00

15

Common stock, $2 par

150,000.00

100,000.00

16

Paid-in capital: Excess of issue price over par—common stock

417,500.00

280,000.00

17

Retained earnings

1,302,940.00

1,202,490.00

18

Total liabilities and stockholders’ equity

$2,361,420.00

$2,059,300.00

The income statement for the year ended December 31, 20Y3, is as follows:

1

Sales

$5,368,400.00

2

Cost of goods sold

3,305,660.00

3

Gross profit

$2,062,740.00

4

Operating expenses:

5

Depreciation expense

$17,180.00

6

Other operating expenses

1,754,452.00

7

Total operating expenses

1,771,632.00

8

Operating income

$291,108.00

9

Other income:

10

Gain on sale of investments

39,110.00

11

Income before income tax

$330,218.00

12

Income tax expense

133,998.00

13

Net income

$196,220.00

Additional data obtained from an examination of the accounts in the ledger for 20Y3 are as follows:

Prepare a statement of cash flows, using the direct method of presenting cash flows from operating activities. Be sure to complete the heading of the statement. Refer to the Labels and Amount Descriptions list provided for the exact wording of the answer choices for text entries. Enter amounts that represent cash outflows as negative numbers using a minus sign.

Prepare a statement of cash flows, using the direct method of presenting cash flows from operating activities. Be sure to complete the heading of the statement. Refer to the Labels and Amount Descriptions list provided for the exact wording of the answer choices for text entries. Enter amounts that represent cash outflows as negative numbers using a minus sign.

Livers Inc.

Statement of Cash Flows

1

Cash flows from operating activities:

2

3

4

5

6

7

8

Cash flows from investing activities:

9

10

11

12

13

14

Cash flows from financing activities:

15

16

17

18

19

Cash at the beginning of the year

20

Cash at the end of the year

1

Dec. 31, 20Y3

Dec. 31, 20Y2

2

Assets

3

Cash

$625,820.00

$586,050.00

4

Accounts receivable (net)

227,530.00

209,880.00

5

Inventories

641,480.00

616,920.00

6

Investments

0.00

240,910.00

7

Land

327,510.00

0.00

8

Equipment

704,830.00

554,110.00

9

Accumulated depreciation-equipment

(165,750.00)

(148,570.00)

10

Total assets

$2,361,420.00

$2,059,300.00

11

Liabilities and Stockholders’ Equity

12

Accounts payable (merchandise creditors)

$424,970.00

$405,330.00

13

Accrued expenses payable (operating expenses)

42,810.00

51,640.00

14

Dividends payable

23,200.00

19,840.00

15

Common stock, $2 par

150,000.00

100,000.00

16

Paid-in capital: Excess of issue price over par—common stock

417,500.00

280,000.00

17

Retained earnings

1,302,940.00

1,202,490.00

18

Total liabilities and stockholders’ equity

$2,361,420.00

$2,059,300.00

Explanation / Answer

Livers Inc

Statement of Cash Flows

For the Years Ending December 31, 2013

2016

Cash Flows from Operating Activities

Net Income

$     1,96,220

Less: Gain on sale of Investment

$      (39,110)

Add Expenses Not Requiring Cash:

    Depreciation

$        17,180

Other Adjustments:

    Subtract increase in Accounts Receivable ($209,880-$227,530)

$      (17,650)

Add increase in Accounts Payable ($424, 970-$405,330)

$        19,640

    Subtract Increase in Inventory ($616,920-$641,480)

$      (24,560)

Subtract reduction in Accrued expense payable ($42,810-$51,640)

$        (8,830)

Net Cash from Operating Activities

$     1,42,890

Cash Flows from Investing Activities

Sale of investments

$     2,80,020

Purchase of New Equipment ($554,110-$704,830)

$    (1,50,720)

Purchase of Land

$    (3,27,510)

Net Cash Used for Investing Activities

$    (1,98,210)

Cash Flows from Financing Activities

Dividend paid

$    (92,410)

Borrowed Long Term Notes Payable

$              -  

Issue of Common stock

$        50,000

Paid in Capital in excess of par

$     1,37,500

Net Cash from Financing Activities

$        95,090

NET INCREASE/(DECREASE) IN CASH

$        39,770

CASH, BEGINNING OF YEAR

$     5,86,050

CASH, END OF YEAR

$     6,25,820

Computation of Dividend paid

Particulars

Amount

Beginning Dividend Payable

$     19,840

Add: Divined Declared

$     95,770

Less: Ending Dividend Payable

$    (23,200)

Dividend Paid

$     92,410

Livers Inc

Statement of Cash Flows

For the Years Ending December 31, 2013

2016

Cash Flows from Operating Activities

Net Income

$     1,96,220

Less: Gain on sale of Investment

$      (39,110)

Add Expenses Not Requiring Cash:

    Depreciation

$        17,180

Other Adjustments:

    Subtract increase in Accounts Receivable ($209,880-$227,530)

$      (17,650)

Add increase in Accounts Payable ($424, 970-$405,330)

$        19,640

    Subtract Increase in Inventory ($616,920-$641,480)

$      (24,560)

Subtract reduction in Accrued expense payable ($42,810-$51,640)

$        (8,830)

Net Cash from Operating Activities

$     1,42,890

Cash Flows from Investing Activities

Sale of investments

$     2,80,020

Purchase of New Equipment ($554,110-$704,830)

$    (1,50,720)

Purchase of Land

$    (3,27,510)

Net Cash Used for Investing Activities

$    (1,98,210)

Cash Flows from Financing Activities

Dividend paid

$    (92,410)

Borrowed Long Term Notes Payable

$              -  

Issue of Common stock

$        50,000

Paid in Capital in excess of par

$     1,37,500

Net Cash from Financing Activities

$        95,090

NET INCREASE/(DECREASE) IN CASH

$        39,770

CASH, BEGINNING OF YEAR

$     5,86,050

CASH, END OF YEAR

$     6,25,820